ClinicalTrials.Veeva

Menu

tDCS and rTMS in Patients With Early Disorders of Consciousness

Capital Medical University logo

Capital Medical University

Status

Not yet enrolling

Conditions

Ischemic-hypoxic Encephalopathy
Stroke
Disorder of Consciousness

Treatments

Device: tDCS
Device: rTMS

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

A randomized controlled study was conducted to explore the efficacy of early transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) to promote wakefulness in patients with disorder of consciousness (DOC). In order to improve the prognosis of DOC patients with nontraumatic brain injury, we compared the effects of tDCS and rTMS on clinical behavior and neurophysiological performance, and selected a wake-up technique that could improve the prognosis of DOC patients with nontraumatic brain injury as early as possible, so as to reduce the pain of patients and their loved ones, and to reduce the economic burden of society and families.

Full description

To study the efficacy of wakefulness promotion in patients with acute DOC due to severe non-traumatic brain injury (including stroke and ischemic-hypoxic encephalopathy), patients with early DOC were randomly divided into conventional treatment group, tDCS treatment group and rTMS treatment group for 14 consecutive days. Clinical scoring, evoked potential assessment, resting-state high-density electroencephalogram(EEG) and TMS-EEG assessment with functional analysis of brain network connectivity were applied for multidimensional assessment of brain function before and after wake-up promotion treatment (day 1 and day 15 of enrollment) to explore non-invasive brain stimulation(NIBS) techniques that can be performed at the bedside - tDCS, rTMS intervention The prognostic follow-up was performed at 3 months, 6 months and 12 months after DOC to compare the awakening rate after tDCS and rTMS prolongation treatment, and to preferably select an effective prolongation technique for early DOC. The safety of tDCS and rTMS was also clarified by comparing the differences in adverse effects and complications between tDCS treatment group and rTMS treatment group and conventional treatment group.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. age 18-80 years
  2. diagnosis of stroke or ischemic-hypoxic encephalopathy confirmed by neuroimaging (head MRI)
  3. DOC, Glasgow coma score (GCS) <12 4.2-4 weeks of DOC

5.informed consent obtained from the patient's legal representative.

Exclusion criteria

  1. foreign bodies such as metal or electronic devices in the skull (inside or on the surface of the tissue at the treatment stimulation site)
  2. pacemaker or cochlear implants
  3. history of epilepsy and family history of epilepsy
  4. large cranial defects
  5. significant cerebral edema lesions in both DLPFC
  6. pregnant women
  7. with severe physical diseases such as heart, lung, liver and kidney
  8. brain death
  9. new intracerebral lesions in patients during the study period affecting the assessment and prognosis, e.g. new stroke

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

120 participants in 3 patient groups

tDCS treatment group
Experimental group
Description:
On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
Treatment:
Device: tDCS
rTMS treatment group
Experimental group
Description:
On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
Treatment:
Device: rTMS
conventional treatment group
No Intervention group
Description:
Not receiving any neuromodulation treatment.

Trial contacts and locations

0

Loading...

Central trial contact

Yan Zhang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems